Pharma BD Deal Intelligence
Biogen closed its $5.6B, $41/share tender for Apellis in May 2026 with 82.4% of shares tendered, picking up Empaveli and Syfovre's $689M combined 2025 revenue to build a new franchise pillar — the CVR's extra $4/share hinges entirely on Syfovre sales through 2031.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Biogen has agreed to spend at least $5.6 billion to diversify its lineup of immune system-regulating drugs through an acquisition of fellow Massachusetts-based…
For Biogen, the Apellis deal marks CEO Chris Viehbacher's largest bet yet to rebuild growth after Spinraza erosion and slower-than-expected Leqembi uptake. The…
Biogen hiked its offer for Apellis Pharmaceuticals multiple times before the two companies agreed to terms on a $5.6 billion acquisition last month. The…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Biogen agreed (Mar 31, 2026) to acquire Apellis for $41/share (~$5.6B equity) plus a CVR of up to $4/share tied to Syfovre global net sales 2027-2031, structured as a tender offer plus back-end merger. The deal CLOSED on May 14, 2026: the tender offer expired May 13 with ~82.4% of shares tendered, the merger completed under Delaware law, and Apellis shares ceased trading on Nasdaq, making Apellis a wholly owned subsidiary of Biogen. The deal adds Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan intravitreal) - $689M combined 2025 net product revenue - to Biogen's portfolio, anchoring an immunology/nephrology growth platform. Financed with cash + debt; Biogen expects accretion to non-GAAP EPS in 2027 and to de-lever by end of 2027.
1.5M US cases/yr · $750M Syfovre + Izervay U.S. net product revenue 2025 (Apellis, Astellas 10-K)
Geographic atrophy (GA) is the advanced, atrophic form of age-related macular degeneration (AMD) characterized by progressive, irreversible loss of retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris in the macula. Per the National Eye Institute (NEI/NIH) and Centers for Disease Control, GA affects approximately 1.5 million Americans, with roughly 160,000 new U.S. cases annually; global prevalence is estimated at 5 million. GA is painless and initially asymptomatic but causes progressive central vision loss, scotomas, reading difficulty, and loss of driving ability, ultimately progressing to legal blindness if central fixation is involved. Age is the dominant risk factor - prevalence rises sharply after age 75 - with additional risk from smoking, family history, European ancestry, and complement pathway genetic variants (CFH, C3, ARMS2). Pathophysiology involves chronic overactivation of the alternative complement pathway, deposition of drusen and complement fragments at the RPE-Bruch's membrane interface, and resulting RPE/photoreceptor death. Diagnosis is by fundus autofluorescence (FAF) and OCT showing characteristic hypoautofluorescent lesions and outer retinal atrophy; lesion growth rate (typically 1.5-2.5 mm^2/year) is the primary efficacy endpoint. Until 2023, no FDA-approved therapy existed - ophthalmologists could only offer AREDS2 vitamins and low-vision rehabilitation. FDA approval of Syfovre (pegcetacoplan, Apellis, Feb 2023) and Izervay (avacincaptad pegol, Astellas/Iveric Bio, Aug 2023) established intravitreal complement inhibition as the first disease-modifying class.
The GA therapeutic landscape was entirely unmet until 2023 and is now a duopoly with emerging challengers. Intravitreal C3 inhibitors: Syfovre (pegcetacoplan, Apellis - the Biogen target) is first-in-class, approved Feb 2023 based on OAKS and DERBY Phase 3 trials showing ~16-22% reduction in GA lesion growth at 24 months with q1m or q2m dosing; generated $599M FY2025 net revenue. Intravitreal C5 inhibitors: Izervay (avacincaptad pegol, Astellas/Iveric Bio) is second-to-market, approved Aug 2023 based on GATHER1/GATHER2, with slightly smaller but comparable lesion-growth slowing; 2025 revenue approximately $150M and growing. Both face real-world uptake headwinds including occlusive retinal vasculitis safety signals (more prominent with Syfovre in post-marketing) and marginal functional visual benefit at interim timepoints. Emerging pipeline: Annexon's ANX007 (anti-C1q intravitreal) reported mixed Phase 3 ARCHER results prioritizing vision endpoints; Alexion/AstraZeneca's danicopan (oral factor D inhibitor) is in Phase 3; Stealth Biotherapeutics' elamipretide (mitochondrial-targeted) has Barth-syndrome approval and a Phase 3 in dry AMD. Gene-therapy entrants - 4D Molecular Therapeutics' 4D-150 and Regenxbio's RGX-314 - target wet AMD primarily but could extend to GA. Biogen's thesis hinges on Syfovre maintaining intravitreal-complement first-mover share against Izervay, oral danicopan, and one-and-done gene therapies.
8K US cases/yr · $3.2B Global complement inhibitor rare-disease revenue 2024 (AstraZeneca/Alexion, Apellis 10-K)
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare acquired clonal hematopoietic stem-cell disorder caused by somatic mutation in the PIGA gene, resulting in deficient GPI-anchored surface proteins (CD55, CD59) on blood cells. Per NORD and the National Heart, Lung, and Blood Institute (NHLBI), U.S. prevalence is estimated at 1-2 per million, translating to roughly 3,000-8,000 prevalent cases. Absent CD55/CD59 renders erythrocytes susceptible to complement-mediated intravascular hemolysis, producing hemoglobinuria, thrombosis (the leading cause of PNH mortality), bone marrow failure, and fatigue. C3 glomerulopathy (C3G), including C3 glomerulonephritis and dense deposit disease, is a separate ultra-rare complement-mediated renal disorder characterized by isolated C3 deposition in glomeruli driven by alternative-complement-pathway dysregulation; U.S. prevalence is approximately 1-2 per million with substantial risk of progression to ESRD. Both diseases share mechanistic dependence on complement C3/C5 activation, making them tractable for targeted complement inhibition. Prior to 2007, PNH was treated with supportive care and allogeneic HSCT; Soliris (eculizumab, anti-C5) transformed the disease with intravascular hemolysis control but left extravascular hemolysis (C3-mediated). Ultomiris (ravulizumab, long-acting anti-C5) extended dosing to q8w. Empaveli (pegcetacoplan, Apellis) was approved 2021 for PNH addressing both intravascular and extravascular hemolysis via proximal C3 inhibition, and received expanded approval in C3G/IgAN in 2025.
Rare complement-mediated hematology/nephrology is dominated by anti-C5 and proximal C3 inhibitors. Anti-C5 monoclonal antibodies: Soliris (eculizumab, AstraZeneca/Alexion) and Ultomiris (ravulizumab, AstraZeneca/Alexion) together generated over $5B in 2024 revenue across PNH, aHUS, gMG, NMOSD, and other indications; Ultomiris is the market leader in PNH with q8w IV dosing. Anti-C5 next-gen: Fabhalta (iptacopan, Novartis) is an oral Factor B inhibitor approved 2023 for PNH and 2024 for C3G, generating ~$400M in 2024 and growing as the first oral complement therapy. Anti-C5 small molecule: Voydeya (danicopan, Alexion/AZ) is an oral add-on to ravulizumab for extravascular hemolysis. Proximal C3 inhibition: Empaveli (pegcetacoplan, Apellis - the Biogen target) is subcutaneous pegylated peptide approved 2021 for PNH and 2025 for C3G/IgAN, with differentiated dual-pathway coverage. Anti-C1s: Sanofi's Enjaymo (sutimlimab) is approved for cold agglutinin disease. Emerging: Alnylam/Regeneron's cemdisiran (C5 siRNA), Amgen's ABP 959 biosimilar, and multiple pre-clinical factor D/B inhibitors. Biogen's acquisition thesis positions Empaveli as a growth asset in oral-therapy-resistant PNH and as the launch asset in C3G where Fabhalta is its principal competitor.
Tender offer expired May 13, 2026 with ~82.4% of shares tendered; back-end Delaware merger completed May 14, 2026. Apellis ceased trading on Nasdaq and became a wholly owned subsidiary of Biogen. Final terms unchanged: $41/share cash + 1 CVR (up to $4/share on Syfovre sales thresholds).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Apellis Pharmaceuticals, Inc. (this deal) | 2026 | $5.6B | — |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
← Browse all deals · How we score deals
More: 2026 deals · Biogen Inc. deals · Nephrology deals